Endometrial Cancer Panel

The test works by analysing mutations in specific genes linked to endometrial cancer.

• The sample is collected from tumor tissue through a biopsy or surgical specimen.
• Advanced genetic sequencing methods are used to detect key mutations in genes such as POLE, TP53, MMR genes (MLH1, MSH2, MSH6, PMS2), PTEN, and others.
• The results help doctors understand the tumor’s biological behavior, which can guide treatment choices.

You may need an endometrial cancer panel test if:

• You have been diagnosed with endometrial cancer and need to understand the genetic profile of the tumor.
• Your doctor suspects genetic mutations that may affect your treatment response.
• You are undergoing treatment and need to check for targetable genetic alterations.

This test is especially helpful for patients with aggressive or recurrent endometrial cancer, as it helps guide personalised treatment strategies.

The endometrial cancer panel detects genetic mutations that are known to contribute to endometrial cancer development and progression:

• Some cases of endometrial cancer may not be linked to genetic mutations and could be influenced by hormonal, lifestyle, or environmental factors.
• The test identifies mutations in key cancer-related genes but does not cover all possible causes of the disease.
• If no mutations are detected, further testing (such as additional molecular tests or imaging studies) may be needed to fully understand the tumor’s behavior.

This test is an important tool, but it should be used alongside other clinical evaluations for a complete diagnosis.